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Background: The present study aims to investigate the potential mechanism of linezolid-resistant Staphylococcus
capitis (LRSC) isolates collected from our hospital.
Methods: The susceptibilities of 5 Staphylococcus capitis isolates displaying resistance towards linezolid were
determined by E-test. Polymerase chain reactions (PCRs) and DNA sequencing were used to investigate the potential
molecular mechanism. Clonal relatedness between these strains was analyzed by pulsed-field gel electrophoresis
(PFGE).
Results: The MICs of linezolid on these 5 isolates were >256 μg/mL. The G2603T mutation was observed in the
domain V of the 23S rRNA with cfr gene being also widely detected among these 5 strains. PFGE analysis displayed
close genetic relatedness between these linezolid-resistant isolates.
Conclusions: The emergence of LRSC isolates carrying G2603T mutation in the domain V of the 23S rRNA and
harboring cfr gene in our hospital may pose a potential challenge to the public health.
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Linezolid is the first member of an entirely new class of
antibiotics that can inhibit bacterial protein synthesis by
binding to the 50S subunit of the bacterial ribosome via
interaction with the 23S rRNA of gram-positive bacteria [1].
Based on the unique mechanism of action, it is highly effect-
ive in the treatment of serious infections caused by antibiotic
resistant gram-positive bacteria such as methicillin-resistant
Staphylococcus aureus and vancomycin-resistant enterococci
[1]. At the introduction of linezolid, it was claimed that
there would be no cross-resistance to linezolid and resist-
ance would be rare and difficult for the bacteria to develop.
However, linezolid-resistant staphylococci and enterococci
have been increasingly reported in recent years [2-5], since* Correspondence: zk60666@163.com
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MRSA in North America in 2001 [6].
The mutations at the central loop of the domain V re-
gion on the 23S rRNA gene have been well recognized
as the main mechanism mediating resistance to linezolid
[6,7]. The acquisition of the chloramphenicol-florfenicol
resistance (cfr) gene encoding the 23S rRNA methyl-
transferase and modifying adenosine at position 2503 in
the 23S rRNA has been frequently reported [2]. In
addition, mutations or deletions in genes encoding the
50S ribosomal subunit proteins L3 or L4 have also
played important role [8-10]. Up to date, the linezolid-
resistant coagulase-negative Staphylococcus (LRCoNS)
isolates have frequently emergenced among patients in
many countries including North America (USA,
Mexico), South America (Brazil), Europe (Greece, Spain,
Italy, France, and Ireland), and Asia (India) [2,5,7,8].
However, such strains have rarely been reported in
China [3,4,11], especially for the linezolid-resistanthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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present study, we report the emergence and potential
clonal dissemination of 5 LRSC isolates among a tertiary
care hospital of China.
Methods
Bacterial strains and data collection
A total of 29 LRSC isolates were continuously recovered
from the blood (n = 28) and catheter (n = 1) from 5 hos-
pitalized patients in 2 different wards at Nanjing Drum
Tower Hospital (Nanjing, China) between September,
2012 and February, 2014. Among them, 5 LRSC isolates
recovered from the blood (n = 4) and catheter (n = 1)
were further analyzed in this study. And 4 linezolid-
susceptible S. capitis (LSSC) isolates (SA01, SA02, SA03,
SA04) from 2 wards during the same period were used
as control. Blood culture was implemented according to
the principle of double-sided bottles, the blood samples
were processed using the BacT/Alert automated system
(bioMerieux, France) and subcultured on Colombia plate
containing 5% sheep blood (bioMerieux, France). Cath-
eter tips were inoculated on Colombia blood agar by roll
pate method. Coagulase-negative Staphylococcus were
identified by colony morphology, gram staining, catalase
testing and coagulase assays. The confirmation of
Staphylococcus capitis was performed by using Vitek 2
Compact GP card (bioMerieux, France) combined with
additional sequencing for the 16S ribosomal ribonucleic
acid (16S rRNA) gene as described below. Clinical data
such as the clinical features, laboratory results, and
treatment were retrieved from the medical records de-
partment. The study protocol was approved by the Eth-
ics Committee of Nanjing Drum Tower Hospital and
written informed consent was obtained from all patients
included in the study.
16S rRNA sequencing for species identification
Chromosomal DNA was extracted from overnight cul-
tures of these isolates grown on Colombia plate contain-
ing 5% sheep blood (bioMerieux, France) using the
Qiagen DNA mini kit (Qiagen, Hilden, Germany), ac-
cording to the manufacturer’s instructions. Molecular
identification of the strains was performed by PCR with
primes of 5′-AGA GTT TGA TCM TGG CTC AG-3′
and 5′-TAC GGY TAC CTT GTT ACG ACT T-3′,
which generated a 1.4- kilobase-pair (kbp) amplicon.
Amplification was carried out using Ex Taq™ DNA poly-
merase (TaKaRa) according to the manufacturer’s in-
struction. The 25 μl reaction mixture for the PCR assays
contained the following: 10 mM Tris/HCL (pH 8.3),
50 mM KCl, 1.5 mM MgCl2, 200 μM deoxynucleotide
triphosphate and 25 pmol of each primer. Amplification
conditions were as follows: 95°C for 5 min, followed by
30 cycles of 95°C for 30 s, 55°C for 30 s and 72°C for1 min as well as 72°C for 10 min. PCR products were se-
quenced by using an ABI 3730XL fluorescence sequencer
(Applied Biosystems, Foster City, Calif.) after they were
purified by using the purification kit (Qiagen, Hilden,
Germany).
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed by using
the disc diffusion tests (Oxoid) on Mueller Hinton agar
(bioMerieux, France) according to Clinical and Laboratory
Standards Institute guidelines [13], with the following anti-
biotics being included: penicillin (30 μg), ampicillin (10 μg),
gentamicin (10 μg), ciprofloxacin (5 μg), levofloxacin
(5 μg), chloromycetin (30 μg), tetracycline (30 μg), cefoxitin
(30 μg), trimethoprim-sulfamethoxazole (25 μg), erythro-
mycin (15 μg), clindamycin (15 μg), ofloxacin (5 μg), ami-
kacin (30 μg), rifampicin (5 μg) and linezolid (30 μg).
Minimum inhibitory concentrations (MICs) of vanco-
mycin, teicoplanin, tigecycline, quinupristin/dalfopristin,
clindamycin and linezolid were determined using CLSI
agar dilution methodology and the MICs of linezolid on
the 5 LRSC isolates was also determined by E-test (AB
Biodisk, Solna, Sweden). S. aureus ATCC 25923 and
29213 were used as the quality controls in parallel.
Molecular detection of resistance genes
Amplification for cfr gene, the domain V of the 23S
rRNA gene and the genes encoding ribosomal proteins
L3, L4 and L22 was implemented as previously described
by Mendes et al. [8]. The amplicons were purified by
using Qiagen DNA purification kit (Qiagen, Hilden,
Germany) and subjected to sequencing. The sequence
similarity was determined by using the BLAST program
from the National Center for Biotechnology Information
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Pulsed-field gel electrophoresis (PFGE)
PFGE was carried out according to the protocol described
by Yang et al. [11] with the CHEF Mapper XA system
(Bio-Rad). Briefly, genomic DNA was digested with Sma-I
and electrophoresis was conducted at 6 V/cm for 22 h at
14°C, with initial and final pulses conducted for 3.0 and
40.0 s, respectively. The PFGE types were defined on the
basis of DNA banding patterns according to the criteria of
Tenover et al. [14].
Results
Clinical data
29 LRSC isolates were collected from these 5 patients.
The number of samples taken from each patient and the
no. of isolates taken has been showed in Table 1. How-
ever, we just took 5 strains including SA10106, SA13096,
SA23062, SA20062, and SA11026 from these 5 patients
respectively for further analysis in our study. As it was
Table 1 The number of samples taken from each patient
and the corresponding strain codes
Patient Ward Strains isolated Resource Collection date
(yy/mm/dd)































Note: ICU: intensive care unit; IDD: the department of infectious diseases.
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SA10106 and SA13096 out of the 5 LRSC isolates were
isolated from different wards during the same time
period, SA23062 and SA20062 from the same wards
during the near time period. However, SA11026 was
isolated in 2014, which was quite later than the previ-
ous 4 isolates. It’s noteworthy that 4 LRSC isolates
were collected from ICU, only 1 from the department
of infectious diseases. In addition, among the 5 pa-
tients carrying LRSC isolates, 3 ones received linezolid
for treatment which lasted more than 13 days with the
total dosage being above 7.8 g.Molecular identification of strains
Further 16S rRNA sequencing and analysis confirmed
that all the 5 LRSC isolates and the 4 LSSC isolates
belonged to S. capitis, which was in accordance with
conventional method. The phylogenetic tree constructed
by neighbor-joining method showed the position of our
isolates with respect to S. capitis strain BQEP2-01d with
the accession number of FJ380956.1.
Antimicrobial susceptibility testing
Similar multidrug-resistant phenotypes were observed in
the 5 LRSC isolates (Table 2). All the 5 isolates were re-
sistant to linezolid indicated both by disk diffusion test-
ing and by the E-test. However, the MICs of vancomycin
and teicoplanin were ≤ 2 μg/mL, and the MICs of tige-
cycline were 0.25 μg/mL. In contrast, all the LSSC iso-
lates showed susceptible to the antimicrobial agents
tested which are quite different from the susceptibilities
of LRSC isolates.
Genetic analysis and resistance-related genes of LRSC
isolates
PCR mapping and sequencing results showed that
G2576T, the most common mutation in domain V of
the 23S rRNA gene [10], was not be detected in all of
the 5 LRSC isolates. However, a new mutation, G2603T,
which had not been previously reported in S. capitis,
was observed in these 5 isolates with the cfr gene being
simultaneously prevalent among them (Table 2), while
none of the 4 LSSC isolates carried cfr gene and had
mutations in the 23S rRNA. Moreover, the mutations in
the L3, L4 or L22 were not detected among LRSC iso-
lates in our current study. The genetic relationship be-
tween these LRSC strains (Figure 1) revealed a clonal
dissemination of LRSC isolates as displayed by the iden-
tical Sma-I digestion patterns.
Discussion
With the frequent use of linezolid in clinical treatment,
the LRCoNS strains have been increasingly isolated from
health care setting. In this study, we report the linezolid
resistance mediated by the G2603T mutations accom-
panied the prevalence of cfr genes in LRSC isolates and
a clonal dissemination of LRSC strain among 5 patients
at a tertiary-care hospital between September 2012 and
February 2014 in Nanjing, Jiangsu province of China.
As it has been previously reported, LRCoNS isolates
only kept sensitivities to vancomycin, teicoplanin, tetra-
cycline, tigecycline and rifampicin in vitro [2]. Previous
report showed that LRCoNS strains were isolated with
the mean time of 11.0 ± 8.0 days after patients were
treated with linezolid, although in a few cases, the resist-
ant strains were acquired as a result of cross-infection
[2]. This may provide further evidence to the proposal













LZD VAN Q/D CLI
SA10106 ICU catheter 2012/9/10 7.8 g/13 days >256 1 >=8 2 + G2603T
SA13096 IDD blood 2012/9/13 – >256 <=0.5 >=8 2 + G2603T
SA23062 ICU blood 2013/6/23 8.4 g/14 days >256 1 >=8 2 + G2603T
SA20062 ICU blood 2013/7/20 13.2 g/22 days >256 <=0.5 >=8 2 + G2603T
SA11026 ICU blood 2014/2/11 – >256 <=0.5 >=8 2 + G2603T
Note: ICU: intensive care unit; IDD: the department of infectious diseases; LZD: linezolid; VAN: vancomycin; Q/D: quinupristin/dalfopristin; CLI: clindamycin; −, no
linezolid treatment.
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development of LRCoNS strains [5]. This has been
partly evidenced by the founding in our study that 3 out
of 5 patients carrying LRSC isolates received linezolid
therapy at least for 13 days with a total dose of 7.8 g be-
fore the isolation of LRSC. Taking into account of the
isolation of the same LRSC clone among these 5 patients
and the time periods of the strains being isolated, weFigure 1 PFGE profiles of Staphylococcus capitis obtained with Sma-I.
SA23062; Line 4, SA20062; Line 5, SA11026; Line 6, SA01; Line 7,SA02; Line 8speculate that it may be a clonal dissemination of LRSC
strain [15].
Generally, cfr methylation confers resistance to 5 clas-
ses of 50S ribosomal subunit-targeted antibiotics defined
by the PhLOPSA phenotype, including phenicols, linco-
samides, oxazolidinones, pleuromutilins, and streptogra-
min A [10]. And cfr-carrying staphylococci therefore
display multi-drug resistant phenotype, which is inM, λ molecular marker; Line 1, SA10106; Line 2, SA13096; Line 3,
, SA03; Line 9, SA04.
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(Table 2). Noteworthily, the cfr gene has been found pri-
marily on plasmids, which can be transferred between
staphylococci. In a recent paper, cfr gene has been de-
scribed to play a decisive role in mediating resistance to li-
nezolid [11]. The identification of a high incidence of cfr
among our LRSC strains indicates a probability of hori-
zontal gene transfer, which alerts us the necessity of
strengthening the implementation of infection and control
measures.
Additionally, previous studies demonstrated that △His
146 and Gly155Arg in L3 in laboratory-derived S. aureus
and mutations within a conserved region of the L4 pro-
tein (63KPWRQKGTGRAR74) have been associated with
cross-resistance to linezolid in Streptococcus pneumo-
niae, S. aureus and Clostridium perfringes [9,16,17].
Nevertheless, such resistance mechanisms were not de-
tected in ribosomal proteins L3, L4 or L22 of the 5
LRSC isolates in our study. Instead, we observed a novel
mutation in the 23S rRNA gene [G(2603)T] which is
quite different from the frequent mutations in the cen-
tral loop of domain V of the 23S rRNA in most
linezolid-resistant isolates, such as enterococci and
staphylococci. As far as we know, G2528U, G2576U, and
G2505A have been identified in linezolid-resistant en-
terococci, G2447U and G2576U in linezolid-resistant S.
aureus [2,10], and C2534T, G2447T, G2576T, T2504A,
C2109T and G2474T in the increasing LRCoNS which
was correlated with nosocomial transmission [2]. It’s
worthy to note that the most common mutation in do-
main V of the 23S rRNA gene, G2576T, was also not de-
tected in our 5 LRSC isolates, whereas, G2603T was
detected in all these 5 isolates. And the presence of
G2603T mutation has been reported to be crucial for
conferring resistance to linezolid in S. epidermidis [18]
and S. hominis subsp. hominis [19]. However, there has
been no report on the G2603T mutation in S. capitis
isolate so far. In addition, it was found that the degree of
linezolid resistance is associated with the number of mu-
tations occurring in the copies of the 23S rRNA coding
gene [20]. In our study, the entire 23S rRNA gene of the
LRSC isolates were not sequenced for all copies, it is
possible that other resistance mechanisms may co-exist
in these strains.
S. capitis has been involved in biofilm related infec-
tions such as endocarditis, urinary tract infection, and
catheter-related bacteremia. Hospital outbreaks caused
by LRCoNS have been reported in the United States,
Ireland, and Spain [21]. It has also been reported that S.
capitis is emerging as an opportunistic pathogen in new-
born babies [22]. The presence of LRSC isolates in
healthcare setting therefore has been a major concern
based on the bacteremia and catheter-related infections
that they frequently caused. Since resistance has mostcommonly occurred in most patients undergoing long-
term linezolid therapy [2], and the heavy use of linezolid
in the patients may create substantial selection pressure in
favor of linezolid-resistant isolate [5]. Thus, prudent use of
linezolid in clinical treatment becomes very important.
Conclusions
In conclusion, the prevalence of cfr gene and the exist-
ence of G2603T mutation together lead to the resistance
of our strains to linezolid. In addition, the clonal dissem-
ination of such LRSCs may pose a potential threat to the
public health.
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